Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
535 questions in 56 reviews · Hypertension
current versionsNo studies 37 · 6.9%Ungraded 34 · 6.4%Very low 91 · 17%Low 161 · 30.1%Moderate 136 · 25.4%High 76 · 14.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR CI: Confidence interval · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aMean baseline values. · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Pitavastatin dose · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | 10 studies · 777 participants | High |
Intervention NR mg/day · participants with normal or abnormal lipid profiles Pitavastatin for lowering lipids (2020) · Cochrane | no estimate extracted | 32 studies · 2789 participants | High |
Effect of high‐dose alcohol vs placebo Systolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 16 studies · 418 participants | Moderate |
Effect of medium‐dose alcohol vs placebo Systolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 10 studies · 149 participants | Moderate |
Effect of medium‐dose alcohol vs placebo Systolic blood pressure ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 54 participants | Low |
Effect of medium‐dose alcohol vs placebo Systolic blood pressure ‐ ≥ 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 5 studies · 66 participants | Low |
Effect of medium‐dose alcohol vs placebo Diastolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 10 studies · 149 participants | Moderate |
Effect of medium‐dose alcohol vs placebo Diastolic blood pressure ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 4 studies · 54 participants | Low |
Effect of medium‐dose alcohol vs placebo Diastolic blood pressure ‐ ≥ 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 5 studies · 66 participants | Moderate |
Effect of medium‐dose alcohol vs placebo Heart rate ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 12 studies · 181 participants | Moderate |
Effect of medium‐dose alcohol vs placebo Heart rate ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 4 studies · 54 participants | Low |
Effect of medium‐dose alcohol vs placebo Heart rate ‐ > 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 3 studies · 36 participants | Low |
Effect of low‐dose alcohol vs placebo Systolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 2 studies · 28 participants | Low |
Effect of high‐dose alcohol vs placebo Systolic blood pressure ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 3 studies · 54 participants | Moderate |
Effect of low‐dose alcohol vs placebo Diastolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 28 participants | Low |
Effect of low‐dose alcohol vs placebo Heart rate ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 2 studies · 28 participants | Moderate |
Effect of high‐dose alcohol vs placebo Systolic blood pressure ‐ ≥ 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 4 studies · 154 participants | Moderate |
Effect of high‐dose alcohol vs placebo Diastolic blood pressure ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 14 studies · 350 participants | Low |
Effect of high‐dose alcohol vs placebo Diastolic blood pressure ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 5 studies · 54 participants | Low |
Effect of high‐dose alcohol vs placebo Diastolic blood pressure ‐ ≥ 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 4 studies · 154 participants | Moderate |
Effect of high‐dose alcohol vs placebo Heart rate ‐ ≤ 6 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 17 studies · 495 participants | Moderate |
Effect of high‐dose alcohol vs placebo Heart rate ‐ 7 to 12 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 7 studies · 144 participants | Moderate |
Effect of high‐dose alcohol vs placebo Heart rate ‐ ≥ 13 hours · adult participants Effect of alcohol on blood pressure (2020) · Cochrane | no estimate extracted | 8 studies · 244 participants | Moderate |
Antihypertensive drug vs placebo or no treatment Total mortality Mean duration of 3.8 years · adults 60 years or older with primary hypertension Pharmacotherapy for hypertension in adults 60 years or older (2019) · Cochrane | RR 0.91 [0.85, 0.97] | 13 studies · 25932 participants | High |
Antihypertensive drug vs placebo or no treatment Cardiovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension Pharmacotherapy for hypertension in adults 60 years or older (2019) · Cochrane | RR 0.72 [0.68, 0.77] | 15 studies · 26747 participants | Moderate |
Antihypertensive drug vs placebo or no treatment Cerebrovascular mortality and morbidity Mean duration of 3.7 years · adults 60 years or older with primary hypertension Pharmacotherapy for hypertension in adults 60 years or older (2019) · Cochrane | RR 0.66 [0.59, 0.74] | 13 studies · 26042 participants | Moderate |
Antihypertensive drug vs placebo or no treatment Coronary heart disease mortality and morbidity Mean duration of 2.9 years · adults 60 years or older with primary hypertension Pharmacotherapy for hypertension in adults 60 years or older (2019) · Cochrane | RR 0.78 [0.69, 0.88] | 11 studies · 24559 participants | Moderate |
Antihypertensive drug vs placebo or no treatment Withdrawals due to adverse effects Mean duration of 4.6 years · adults 60 years or older with primary hypertension Pharmacotherapy for hypertension in adults 60 years or older (2019) · Cochrane | RR 2.91 [2.56, 3.3] | 4 studies · 11310 participants | Low |
First‐line low‐dose thiazide vs placebo Total mortality · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 8 studies · 19874 participants | High |
First‐line high‐dose thiazide vs placebo Withdrawal due to adverse effects · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 7 studies · 15170 participants | Low |
First‐line beta‐blocker vs placebo Total mortality · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.96 [0.86, 1.07] | 5 studies · 19313 participants | Moderate |
First‐line beta‐blocker vs placebo Total stroke · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.83 [0.72, 0.97] | 5 studies · 19313 participants | Low |
First‐line beta‐blocker vs placebo Total coronary heart disease · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.9 [0.78, 1.03] | 5 studies · 19313 participants | Low |
First‐line beta‐blocker vs placebo Total cardiovascular events · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.89 [0.81, 0.98] | 5 studies · 19313 participants | Low |
First‐line beta‐blocker vs placebo Withdrawal due to adverse effects · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 4.59 [4.11, 5.13] | 4 studies · 18565 participants | Low |
First‐line angiotensin converting enzyme inhibitor vs placebo Total mortality · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.83 [0.72, 0.95] | 3 studies · 6002 participants | Moderate |
First‐line angiotensin converting enzyme inhibitor vs placebo Total stroke · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.65 [0.52, 0.82] | 3 studies · 6002 participants | Low |
First‐line angiotensin converting enzyme inhibitor vs placebo Total coronary heart disease · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.81 [0.7, 0.94] | 2 studies · 5145 participants | Moderate |
First‐line angiotensin converting enzyme inhibitor vs placebo Total cardiovascular events · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.76 [0.67, 0.85] | 2 studies · 5145 participants | Moderate |
First‐line low‐dose thiazide vs placebo Total stroke · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 8 studies · 19874 participants | High |
First‐line calcium channel blocker vs placebo Total mortality · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.86 [0.68, 1.09] | 1 study · 4695 participants | Low |
First‐line calcium channel blocker vs placebo Total stroke · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.58 [0.41, 0.84] | 1 study · 4695 participants | Low |
First‐line calcium channel blocker vs placebo Total coronary heart disease (CHD) · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.77 [0.55, 1.09] | 1 study · 4695 participants | Low |
First‐line calcium channel blocker vs placebo Total cardiovascular events · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | RR 0.71 [0.57, 0.87] | 1 study · 4695 participants | Low |
First‐line low‐dose thiazide vs placebo Total coronary heart disease · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 7 studies · 19022 participants | High |
First‐line low‐dose thiazide vs placebo Total cardiovascular events · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 7 studies · 19022 participants | High |
First‐line low‐dose thiazide vs placebo Withdrawal due to adverse effects · adult patients with primary hypertension First‐line drugs for hypertension (2018) · Cochrane | no estimate extracted | 3 studies · 8870 participants | Low |